HIK.L Stock — Price, Charts & Analysis

Hikma Pharmaceuticals PLC (HIK.L) has a trailing P/E of 12.49x and a forward P/E of 8.86x. This places HIK.L in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

HIK.L trades with 12.49x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether HIK.L looks overvalued or undervalued.

HIK.L's P/E of 12.49x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

HIK.L's trailing EPS is £1.30 and forward EPS is £1.83. Reported earnings growth is -4.70%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Hikma Pharmaceuticals PLC generated for each share. HIK.L's trailing EPS is £1.30, and investors usually prefer EPS that is positive and growing over time.

Hikma Pharmaceuticals PLC has a market cap of £3.37B, making HIK.L a mid-cap stock based on the current market value shown on Worldtickers.

HIK.L's latest stock price on Worldtickers is £1,624.00. The latest move is -£34.00 or -2.05%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

HIK.L's quote includes a latest price of £1,624.00. The market open is £0.00. Previous close is £1,658.00. The intraday range is £0.00 to £0.00.

HIK.L is down in the latest quote, with a move of -£34.00 or -2.05%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

HIK.L generated £3.42B in trailing revenue. Revenue growth is 4.20%, which helps show whether demand is expanding or slowing.

HIK.L's revenue growth is 4.20%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, HIK.L shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is £387.00M.

Gross margin is 44.05%. Margins show how efficiently Hikma Pharmaceuticals PLC turns revenue into profit.

Hikma Pharmaceuticals PLC carries £1.96B and holds £289.00M in cash.

HIK.L holds £289.00M on its balance sheet.

HIK.L's book value per share is £8.57.

Yes, Hikma Pharmaceuticals PLC pays a dividend of £0.63 per share annually. The dividend yield is 383.00%. The payout ratio is 46.87%.

HIK.L's dividend yield is 383.00%. Its payout ratio is 46.87%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for HIK.L. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Hikma Pharmaceuticals PLC's investor relations materials.

HIK.L's five-year average dividend yield is 290.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 36.48% of HIK.L shares. Insiders hold 32.91% of shares. Ownership mix helps investors understand how much of Hikma Pharmaceuticals PLC is held by professional investors and company insiders.

HIK.L has 207.23M shares outstanding. Float shares are 146.44M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for HIK.L, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for HIK.L is £1.83. Earnings growth is -4.70%. Revenue growth is 4.20%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

HIK.L's trailing EPS is £1.30. Forward EPS is £1.83. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

HIK.L is in the Healthcare sector. Its earnings multiple is 12.49x. Its latest displayed growth metric is 4.20%. Compare these figures with sector peers before deciding whether Hikma Pharmaceuticals PLC is stronger or weaker than average.

HIK.L trades at £1,624.00. The stock trades at 12.49x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Hikma Pharmaceuticals PLC's fundamentals.

HIK.L risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.66, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

HIK.L should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 12.49x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Hikma Pharmaceuticals PLC (HIK.L) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for th

HIK.L trades on LSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

HIK.L stock is priced in GBp on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Hikma Pharmaceuticals PLC's official website listed on Worldtickers is www.hikma.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Hikma Pharmaceuticals PLC employs about 9.5K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Hikma Pharmaceuticals PLC is headquartered in London, United Kingdom. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

HIK.L is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

HIK.L has traded between £0.00 and £1,865.00 over the past 52 weeks. At £1,624.00, it is 12.92% below the high and 0.00% above the low. The 52-week range helps gauge long-term price momentum.

HIK.L is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is £1,565.78 and its 200-day moving average is £1,489.94.

HIK.L's RSI is 60.14. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

HIK.L's latest RSI reading is 60.14, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for HIK.L is near £1,511.65. Key resistance is near £1,754.60. Breaks above resistance or below support can change the short-term technical setup.

HIK.L's nearest reported support level is £1,511.65. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

HIK.L's nearest reported resistance level is £1,754.60. A breakout above resistance can improve momentum, especially when volume confirms the move.

HIK.L trades about 1.06M shares daily on average. The latest displayed volume is 64.85K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

HIK.L's MACD is -0.06, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

HIK.L is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 60.14 (neutral). MACD is bearish. Nearest support is around £1,511.65. Resistance is around £1,754.60. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is £1,619.77 (2.36% from price). MA50 is £1,565.78 (5.89% from price). MA200 is £1,489.94 (11.28% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. HIK.L's MA20 is £1,619.77. MA50 is £1,565.78. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

HIK.L's pivot is near £1,646.00. Support is near £1,511.65. Resistance is near £1,754.60. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for HIK.L is near £1,607.13. The next upper resistance zone is near £1,758.09. These levels help define risk and possible follow-through zones after a breakout or breakdown.

HIK.L's Bollinger range is roughly £1,540.79 to £1,698.75. Band width is near 9.75%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

HIK.L's ATR-based typical daily range is about 2.69%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 64.85K shares. Average volume is about 1.06M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

HIK.L's all-time high shown on Worldtickers is £2,768.00. Its all-time low is £225.00. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

HIK.L has a beta of 0.66, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.